| 39.36 -1.64 (-4%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 58.94 | 1-year : | 68.85 |
| Resists | First : | 50.47 | Second : | 58.94 |
| Pivot price | 43.55 |
|||
| Supports | First : | 35.32  |
Second : | 25.96 |
| MAs | MA(5) : | 41.12 |
MA(20) : | 44.5 |
| MA(100) : | 25.18 |
MA(250) : | 27.11 |
|
| MACD | MACD : | 2.1 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 11.7 |
D(3) : | 15.9 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 71.5 | Low : | 8.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ QURE ] has closed above bottom band by 12.6%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 40.62 - 40.85 | 40.85 - 41.1 |
| Low: | 38.37 - 38.62 | 38.62 - 38.9 |
| Close: | 38.88 - 39.32 | 39.32 - 39.8 |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Thu, 16 Jul 2026
JPMorgan discloses 7% uniQure (QURE) stake of 4,866,211 shares - Stock Titan
Thu, 16 Jul 2026
What Caused uniQure's Dramatic Stock Plunge - Kavout | AI
Tue, 14 Jul 2026
QURE Stock Just Shot Up 8% - uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Tue, 14 Jul 2026
If You Invested $1,000 in Uniqure (QURE) - Stock Titan
Wed, 01 Jul 2026
Price to earnings forward of uniQure N.V. – NASDAQ:QURE - TradingView
Thu, 25 Jun 2026
UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 5.653e+007 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 11,100 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7486e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 321.1 % |
| Return on Equity (ttm) | -17 % |
| Qtrly Rev. Growth | 1.809e+007 % |
| Gross Profit (p.s.) | 141.44 |
| Sales Per Share | -253.61 |
| EBITDA (p.s.) | -1.26256e+008 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -172 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.16 |
| Price to Cash Flow | 14.94 |
| Dividend | 0 |
| Forward Dividend | 1.149e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|